- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06448637
LÆGEMIDDELAFGIVENDE KUGLE vs. FARMAKOAKTIV STENT I STORE FAR: MORFOLOGISK ANALYSE OG FUNKTION VASOMOTOR (DEBORA STUDIE) I STORE FARBEJER: MORFOLOGISK ANALYSE OG FUNKTION VASOMOTOR (DEBORA STUDIE)
LÆGEMIDDELAFGIVENDE KUGLE vs. FARMAKOAKTIV STENT I STORE FARTØJER: MORFOLOGISK ANALYSE OG FUNKTIONSVASOMOTOR (DEBORA-STUDIE)
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Randomized, controlled, open and multicenter study that analyzes the vasomotor function 8 months after use of the drug-eluting balloon (DCB) vs. drug-eluting stent (DES) in vessels ≥ 3.5 mm
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: FUNDACION EPIC
- Telefonnummer: 0034987876135
- E-mail: iepic@fundacionepic.org
Undersøgelse Kontakt Backup
- Navn: IÑIGO LOZANO MARTINEZ-LUENGAS, MD, PhD
- Telefonnummer: 0034630901145
- E-mail: inigo.lozano@fundacionepic.org
Studiesteder
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Gijón, Spanien, 33394
- Rekruttering
- Hospital Universitario de Cabueñes
-
Huelva, Spanien, 21005
- Rekruttering
- Hospital Universitario Juan Ramón Jiménez
-
León, Spanien, 24008
- Rekruttering
- Hospital Universitario de Leon
-
Lugo, Spanien, 270003
- Rekruttering
- Hospital Universitario Lucus Augusti
-
Mérida, Spanien, 06800
- Rekruttering
- Hospital de Merida
-
Oviedo, Spanien, 33011
- Rekruttering
- Hospital Universitario Central de Asturias
-
Pontevedra, Spanien, 36071
- Rekruttering
- Hospital Provincial de Pontevedra
-
Tarragona, Spanien, 43005
- Rekruttering
- Hospital Universitari de Tarragona Joan XXIII
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Patients who meet all of the following conditions are included.
- Patients aged ≥ 18 years and;
- Patients with chronic coronary syndrome, acute coronary syndrome without ST segment elevation or acute coronary syndrome with elevation ST segment in non-culprit lesions 48 hours after the event and;
- Patients with de novo lesions in vessels ≥ 3.5 mm without calcification significant no visible thrombus and;
- Patients who have been informed of the characteristics of the study and have provided their written informed consent.
Exclusion Criteria:
Patients who meet at least one of the following conditions are excluded:
- Patients with any contraindication for the administration of acetylcholine (ACh) or nitroglycerin (NTG).
- Patients with a history of coronary vasospasm or spontaneous dissection of the coronary artery.
- Patients with significant medical, surgical or psychiatric condition that would affect the safety of the subject or influence the outcome of the study according to the doctor's opinion.
- Patients who received a combination of DES and DCB in the same vessel
- Patients with glomerular filtration rate <30 ml/min/ 1.73 m2
- Patients with body mass index >35 (may affect the evaluation qualitative diameter of the coronary artery).
- Patients with symptomatic congestive heart failure.
- Patients with significant autoimmune inflammatory conditions and patients taking immunomodulatory medications (including methotrexate, cyclosporine, steroids).
- Patients with heart transplant.
- Patients with anemia (Hb <12 g/dL in men and <10 g/dL in women).
- Patients, women of childbearing age with a positive pregnancy test.
- Pregnant female patients.
- Patients included in other clinical trials with active follow-up.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Drug Coated Balloon (DCB)
Drug Coated Balloon (DCB) |
Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI) |
|
Eksperimentel: Drug Eluting Stent (DES)
Drug Eluting Stent (DES) |
Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L).
Tidsramme: 8 months
|
Percentage of vessels with a positive response to Ach, defined as >4% change in the mean luminal diameter observed in the coronary segment distal (10-30 mm) to the treated segment, after the infusion of the maximum dose of ACh (10-6 mol/L). |
8 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of percentage of angiographic restenosis by quantitative coronary
Tidsramme: 8 months
|
Comparison of percentage of angiographic restenosis by quantitative coronary |
8 months
|
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography
Tidsramme: 8 months
|
Comparison of the minimum luminal diameter of the treated segment by optical coronary tomography |
8 months
|
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography
Tidsramme: 8 months
|
Comparison of the minimum luminal area of the treated segment by optical coronary tomography |
8 months
|
|
Percentage of of strut coverage by OCT(Optical Coherence Tomography) in the DES group
Tidsramme: 8 months
|
Percentage of of strut coverage by OCT in the DES group |
8 months
|
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months
Tidsramme: 8 months
|
Percentage of vessels with normal vascular architecture with correct definition of intima and media by optical coherence tomography in the drug-coated balloon group at 8 months |
8 months
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046.
- Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, King SB 3rd, Chronos N, Hou D. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. 2011 Feb;4(2):247-55. doi: 10.1016/j.jcin.2010.08.028.
- Gutierrez E G-LJ, Escaned J, Cruz I, Ojeda S, Romaguera R, Moreno R. Valoración de la función endotelial y provocación de vasoespasmo coronario mediante infusión intracoronaria de acetilcolina. Documento técnico de la ACI-SEC. REC Interv Cardiol. 2021;3(4):286-296.
- Gomez-Lara J, Oyarzabal L, Ortega-Paz L, Brugaletta S, Romaguera R, Salvatella N, Roura G, Rivero F, Fuentes L, Alfonso F, Otaegui I, Vandeloo B, Vaquerizo B, Sabate M, Comin-Colet J, Gomez-Hospital JA. Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. J Am Heart Assoc. 2021 Nov 16;10(22):e022123. doi: 10.1161/JAHA.121.022123. Epub 2021 Nov 3.
- Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012 Jun;33(11):1325-33. doi: 10.1093/eurheartj/ehr466. Epub 2012 Apr 16.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EPIC37-DEBORA
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .